ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)

NCT05630612 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

ANCA Associated Vasculitis
Cardiovascular Diseases
Kidney Diseases

Interventions

DRUG: Sparsentan

Sponsor

University of Edinburgh

Collaborators

[object Object]